



# MEDICINES NOTIFICATION

## CLASS 4 MEDICINES DEFECT INFORMATION

**Caution in Use**  
**Distribute to Pharmacy / Wholesaler Level**

Date: 09 July 2024

EL (24)A/27

Our Ref: DMRC-30829551

Dear Healthcare Professional,

### Chelonia Healthcare Limited

**Proprantheline Tablets 15mg (Genesis Pharmaceuticals livery)**

**PL 33414/0094**

**SNOMED Code** 42639811000001102

Batch Number	Expiry Date	Pack Size	First Distributed
2308089	Jul-26	112 tablets	29-Jan-2024
2308090	Jul-26	112 tablets	07-Feb-2024
2402100	Jan-27	112 tablets	30-May-2024
2402106	Feb-27	112 tablets	30-May-2024
2402111	Feb-27	112 tablets	01-Jun-2024
2402112	Feb-27	112 tablets	01-Jun-2024
2402107	Feb-27	112 tablets	24-Jun-2024
2402108	Feb-27	112 tablets	24-Jun-2024
2402109	Feb-27	112 tablets	24-Jun-2024
2402110	Feb-27	112 tablets	24-Jun-2024

Active Pharmaceutical Ingredient: proprantheline bromide

#### Brief description of the problem

Chelonia Healthcare Limited has informed the MHRA that an error relating to the product description was identified in the Patient Information Leaflet (PIL) for the batches listed in this notification. In the PIL supplied, the product is described in Section 6 as being “pale pink in colour”, whereas the tablet is actually orange in colour.

#### Advice for healthcare professionals

There is no risk to product quality or safety because of this issue. Therefore the affected batches are not being recalled. Due to supply considerations, batches 2402107, 2402108, 2402109 and 2402110 have been recently distributed and were not repackaged with the updated PIL prior to distribution. Chelonia Healthcare Limited has confirmed that all future batches of the product will contain an updated PIL.

Healthcare professionals, including those involved in prescribing and dispensing, should note the correct description of the tablets as “**round and convex in shape, and orange in colour**”, as shown in the images below.



### Advice for patients

Patients do not need to take any action. The medicine itself is not affected. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients receiving the medicine via dosette boxes should continue to take the medicine in line with their prescription.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should be reported via the MHRA [Yellow Card scheme](#).

### Further Information

For stock control queries please contact [info@genesis-pharma.com](mailto:info@genesis-pharma.com) (Tel 020 7201 0400)

For Medical queries please contact [eupvg@genreg.eu](mailto:eupvg@genreg.eu) (Tel: 020 7201 0421).

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

**Defective Medicines Report Centre**  
**10 South Colonnade**  
**Canary Wharf**  
**London**  
**E14 4PU**  
**Telephone +44 (0)20 3080 6574**  
[DMRC@mhra.gov.uk](mailto:DMRC@mhra.gov.uk)